Armata Pharmaceuticals Inc (ARMP)

$7.74 +1.04 (15.52%)
Market Cap 243.93M
Revenue (ttm) 5.17M
Net Income (ttm) -18.92M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -365.96%
Debt to Equity Ratio -1.53
Volume 45,600
Avg Vol 49,778
Day's Range N/A - N/A
Shares Out 36.41M
Stochastic %K 97%
Beta 1.29
Analysts Strong Sell
Price Target $12.00

Company Profile

Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has research collaboration agreement...

Industry: Biotechnology
Sector: Healthcare
Phone: 310 665 2928
Fax: 310 665 2963
Address:
5005 McConnell Avenue, Los Angeles, United States
Trapped
Trapped Feb. 3 at 11:03 AM
$ARMP hmmm past 7 already. looks like heading to 15 again before phase 3 concludes. could there be a buyer in the wings ??? p
0 · Reply
Trapped
Trapped Feb. 2 at 10:37 PM
$ARMP a lot more coming. phase 3 going on with FDA do execute in LA office. going to be a good drug once it’s approved. just gotta wait. mean time value will continue to head north. buy and hold.
0 · Reply
History101
History101 Feb. 2 at 9:02 PM
$ARMP damn, closed today with a 15% gain, glad i added earlier today. Anyone know why the big gain today?
0 · Reply
Trapped
Trapped Feb. 2 at 6:39 PM
$ARMP i think we see $50 by end of this year.
0 · Reply
History101
History101 Feb. 2 at 5:55 PM
$ARMP $7!!
0 · Reply
Trapped
Trapped Jan. 28 at 11:30 AM
$ARMP 7 …here we come
0 · Reply
ConnorCapital
ConnorCapital Jan. 19 at 3:44 PM
$ARMP Low attention, but a break above could lead to a breakout
0 · Reply
BillionerOfKing
BillionerOfKing Jan. 16 at 8:36 PM
$ARMP Current Stock Price: $6.41 No option chain rows found for expiry 2026-01-16.
0 · Reply
King_of_the_bagholders
King_of_the_bagholders Jan. 16 at 2:41 PM
$OCG FUCK I’m good! Now if we can just get $ARMP pumping again…
0 · Reply
King_of_the_bagholders
King_of_the_bagholders Jan. 15 at 6:23 PM
$ARMP $NVO $OPEN $VZ the 7.50 options are still at a steep discount RN Not financial advice
0 · Reply
Latest News on ARMP
Armata Pharmaceuticals Announces End-of-Phase 2 Meeting with FDA and Plans to Advance AP-SA02 to a Phase 3 Superiority Study in Complicated BacteremiaStaphylococcusaureus

Jan 13, 2026, 7:00 AM EST - 21 days ago

Armata Pharmaceuticals Announces End-of-Phase 2 Meeting with FDA and Plans to Advance AP-SA02 to a Phase 3 Superiority Study in Complicated BacteremiaStaphylococcusaureus

Armata Pharmaceuticals Announces Key Opinion Leader Webinar on S. aureus Bacteremia and AP-SA02 Hosted by Jones Research on November 25th at 10:00am EST

Nov 18, 2025, 7:00 AM EST - 2 months ago

Armata Pharmaceuticals Announces Key Opinion Leader Webinar on S. aureus Bacteremia and AP-SA02 Hosted by Jones Research on November 25th at 10:00am EST

Armata Pharmaceuticals Announces Third Quarter 2025 Results and Provides Corporate Update

Nov 12, 2025, 4:05 PM EST - 2 months ago

Armata Pharmaceuticals Announces Third Quarter 2025 Results and Provides Corporate Update

Armata Pharmaceuticals Announces Formal Commissioning of State-of-the-Art cGMP Phage Manufacturing Facility in Los Angeles, California

Nov 10, 2025, 7:00 AM EST - 3 months ago

Armata Pharmaceuticals Announces Formal Commissioning of State-of-the-Art cGMP Phage Manufacturing Facility in Los Angeles, California

Armata Pharmaceuticals Highlights Positive Results from Phase 2a diSArm Study of its Staphylococcus aureus Bacteriophage Cocktail, AP-SA02, in Late-Breaking Oral Presentation at IDWeek 2025™

Oct 22, 2025, 11:10 AM EDT - 3 months ago

Armata Pharmaceuticals Highlights Positive Results from Phase 2a diSArm Study of its Staphylococcus aureus Bacteriophage Cocktail, AP-SA02, in Late-Breaking Oral Presentation at IDWeek 2025™

Armata Pharmaceuticals to Present Late-Breaking Clinical Data highlighting its Staphylococcus aureus Bacteriophage Cocktail, AP-SA02, at IDWeek 2025™

Oct 14, 2025, 7:00 AM EDT - 4 months ago

Armata Pharmaceuticals to Present Late-Breaking Clinical Data highlighting its Staphylococcus aureus Bacteriophage Cocktail, AP-SA02, at IDWeek 2025™

Armata Pharmaceuticals Announces Structural Biology Publication in the Journal of Molecular Biology

Sep 8, 2025, 7:00 AM EDT - 5 months ago

Armata Pharmaceuticals Announces Structural Biology Publication in the Journal of Molecular Biology

Armata Pharmaceuticals to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Sep 4, 2025, 7:00 AM EDT - 5 months ago

Armata Pharmaceuticals to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Armata Pharmaceuticals Announces Second Quarter 2025 Results and Provides Corporate Update

Aug 12, 2025, 4:05 PM EDT - 6 months ago

Armata Pharmaceuticals Announces Second Quarter 2025 Results and Provides Corporate Update

Armata Pharmaceuticals Announces Positive Topline Data from the Phase 1b/2a diSArm Study of Intravenously Administered AP-SA02 in Complicated Staphylococcus aureus Bacteremia

May 19, 2025, 7:00 AM EDT - 9 months ago

Armata Pharmaceuticals Announces Positive Topline Data from the Phase 1b/2a diSArm Study of Intravenously Administered AP-SA02 in Complicated Staphylococcus aureus Bacteremia

Armata Pharmaceuticals Announces First Quarter 2025 Results and Provides Corporate Update

May 14, 2025, 4:05 PM EDT - 9 months ago

Armata Pharmaceuticals Announces First Quarter 2025 Results and Provides Corporate Update

Armata Pharmaceuticals Receives $4.65 Million of Additional Non-Dilutive Award Funding from the U.S. Department of Defense to Support Ongoing diSArm Clinical Trial of AP-SA02

May 1, 2025, 7:00 AM EDT - 9 months ago

Armata Pharmaceuticals Receives $4.65 Million of Additional Non-Dilutive Award Funding from the U.S. Department of Defense to Support Ongoing diSArm Clinical Trial of AP-SA02

Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2024 Results and Provides Corporate Update

Mar 20, 2025, 5:56 PM EDT - 11 months ago

Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2024 Results and Provides Corporate Update

Armata Pharmaceuticals Announces $10 Million Secured Credit Agreement with Innoviva

Mar 12, 2025, 5:08 PM EDT - 11 months ago

Armata Pharmaceuticals Announces $10 Million Secured Credit Agreement with Innoviva

INVA

Armata Pharmaceuticals Announces that CEO Dr. Deborah Birx Will Deliver a Presentation at the 7th Annual Bacteriophage Therapy Summit

Mar 11, 2025, 7:00 AM EDT - 11 months ago

Armata Pharmaceuticals Announces that CEO Dr. Deborah Birx Will Deliver a Presentation at the 7th Annual Bacteriophage Therapy Summit

Armata Pharmaceuticals Announces Encouraging Results from the Phase 2 Tailwind Study of Inhaled AP-PA02 in Non-Cystic Fibrosis Bronchiectasis Subjects with Chronic Pulmonary Pseudomonas aeruginosa Infection

Dec 19, 2024, 7:00 AM EST - 1 year ago

Armata Pharmaceuticals Announces Encouraging Results from the Phase 2 Tailwind Study of Inhaled AP-PA02 in Non-Cystic Fibrosis Bronchiectasis Subjects with Chronic Pulmonary Pseudomonas aeruginosa Infection

Armata Pharmaceuticals Announces that CEO Dr. Deborah Birx Will Deliver a Presentation at the 5th Annual Phage Futures Annual Meeting

Nov 19, 2024, 7:00 AM EST - 1 year ago

Armata Pharmaceuticals Announces that CEO Dr. Deborah Birx Will Deliver a Presentation at the 5th Annual Phage Futures Annual Meeting

Armata Pharmaceuticals Announces Third Quarter 2024 Results and Provides Corporate Update

Nov 13, 2024, 4:05 PM EST - 1 year ago

Armata Pharmaceuticals Announces Third Quarter 2024 Results and Provides Corporate Update

Armata Pharmaceuticals Announces the Completion of Enrollment of its Phase 1b/2a diSArm Study Evaluating Intravenous AP-SA02 as a Potential Treatment for Staphylococcus aureus Bacteremia

Nov 12, 2024, 7:00 AM EST - 1 year ago

Armata Pharmaceuticals Announces the Completion of Enrollment of its Phase 1b/2a diSArm Study Evaluating Intravenous AP-SA02 as a Potential Treatment for Staphylococcus aureus Bacteremia

Armata Pharmaceuticals Announces Structural Biology Publication

Oct 30, 2024, 7:00 AM EDT - 1 year ago

Armata Pharmaceuticals Announces Structural Biology Publication

Armata Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

Sep 5, 2024, 7:30 AM EDT - 1 year ago

Armata Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

Armata Pharmaceuticals Announces Presentation at the 2024 Military Health System Research Symposium

Aug 26, 2024, 7:30 AM EDT - 1 year ago

Armata Pharmaceuticals Announces Presentation at the 2024 Military Health System Research Symposium

Armata Pharmaceuticals Announces Appointment of Life Sciences Accounting and Finance Veteran David House as SVP of Finance and Principal Financial Officer

Aug 15, 2024, 4:45 PM EDT - 1 year ago

Armata Pharmaceuticals Announces Appointment of Life Sciences Accounting and Finance Veteran David House as SVP of Finance and Principal Financial Officer

Armata Pharmaceuticals Announces Second Quarter 2024 Results and Provides Corporate Update

Aug 13, 2024, 4:05 PM EDT - 1 year ago

Armata Pharmaceuticals Announces Second Quarter 2024 Results and Provides Corporate Update

Armata Pharmaceuticals Receives $5.25 Million of Additional Non-Dilutive Grant Funding from the U.S. Department of Defense to Support Ongoing diSArm Clinical Trial of AP-SA02

Jul 30, 2024, 7:00 AM EDT - 1 year ago

Armata Pharmaceuticals Receives $5.25 Million of Additional Non-Dilutive Grant Funding from the U.S. Department of Defense to Support Ongoing diSArm Clinical Trial of AP-SA02

Armata Pharmaceuticals Announces Completion of Enrollment of Phase 2 Tailwind Study of Inhaled AP-PA02 in Non-Cystic Fibrosis Bronchiectasis Subjects with Chronic Pulmonary Pseudomonas aeruginosa Infection

Jul 11, 2024, 7:00 AM EDT - 1 year ago

Armata Pharmaceuticals Announces Completion of Enrollment of Phase 2 Tailwind Study of Inhaled AP-PA02 in Non-Cystic Fibrosis Bronchiectasis Subjects with Chronic Pulmonary Pseudomonas aeruginosa Infection

Armata Pharmaceuticals Announces Presentation at Viruses of Microbes 2024

Jul 10, 2024, 4:05 PM EDT - 1 year ago

Armata Pharmaceuticals Announces Presentation at Viruses of Microbes 2024

Armata Pharmaceuticals Announces First Quarter 2024 Results and Provides Corporate Update

May 7, 2024, 4:01 PM EDT - 1 year ago

Armata Pharmaceuticals Announces First Quarter 2024 Results and Provides Corporate Update

Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2023 Results and Provides Corporate Update

Mar 21, 2024, 4:05 PM EDT - 2 years ago

Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2023 Results and Provides Corporate Update

Armata Pharmaceuticals Announces $35 Million Secured Credit Agreement with Innoviva

Mar 4, 2024, 4:01 PM EST - 2 years ago

Armata Pharmaceuticals Announces $35 Million Secured Credit Agreement with Innoviva

INVA

Armata Pharmaceuticals Announces Presentation at the 6th Annual Bacteriophage Therapy Summit

Feb 21, 2024, 7:00 AM EST - 2 years ago

Armata Pharmaceuticals Announces Presentation at the 6th Annual Bacteriophage Therapy Summit

Armata Pharmaceuticals Announces Third Quarter 2023 Results and Provides Corporate Update

Nov 14, 2023, 4:00 PM EST - 2 years ago

Armata Pharmaceuticals Announces Third Quarter 2023 Results and Provides Corporate Update

Armata Pharmaceuticals Announces Presentation of Topline Data from SWARM-P.a. Clinical Study at the North American Cystic Fibrosis Conference

Oct 30, 2023, 8:00 AM EDT - 2 years ago

Armata Pharmaceuticals Announces Presentation of Topline Data from SWARM-P.a. Clinical Study at the North American Cystic Fibrosis Conference

Armata Pharmaceuticals Announces Presentation at Phage Futures: Global Digital Summit 2023

Oct 19, 2023, 8:00 AM EDT - 2 years ago

Armata Pharmaceuticals Announces Presentation at Phage Futures: Global Digital Summit 2023

Armata Pharmaceuticals Announces First Patient Dosed in the Phase 2a Portion of the Phase 1b/2a 'diSArm' Study of AP-SA02 in Adults with Bacteremia Due to Staphylococcus aureus

Sep 26, 2023, 8:00 AM EDT - 2 years ago

Armata Pharmaceuticals Announces First Patient Dosed in the Phase 2a Portion of the Phase 1b/2a 'diSArm' Study of AP-SA02 in Adults with Bacteremia Due to Staphylococcus aureus

Armata Pharmaceuticals to Participate in the Cantor Global Healthcare Conference

Sep 21, 2023, 7:00 AM EDT - 2 years ago

Armata Pharmaceuticals to Participate in the Cantor Global Healthcare Conference

Armata Pharmaceuticals Announces Second Quarter 2023 Results and Provides Corporate Update

Aug 14, 2023, 7:00 AM EDT - 2 years ago

Armata Pharmaceuticals Announces Second Quarter 2023 Results and Provides Corporate Update

Armata Pharmaceuticals Announces Oral Presentation Detailing Results from the Phase 1b/2a SWARM-P.a. Clinical Trial at the 6th World Conference on Targeting Phage Therapy

May 31, 2023, 8:00 AM EDT - 2 years ago

Armata Pharmaceuticals Announces Oral Presentation Detailing Results from the Phase 1b/2a SWARM-P.a. Clinical Trial at the 6th World Conference on Targeting Phage Therapy

Armata Pharmaceuticals Announces First Quarter 2023 Results and Provides Corporate Update

May 11, 2023, 4:05 PM EDT - 2 years ago

Armata Pharmaceuticals Announces First Quarter 2023 Results and Provides Corporate Update

Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2022 Results and Provides Corporate Update

Mar 16, 2023, 4:10 PM EDT - 3 years ago

Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2022 Results and Provides Corporate Update

Armata Pharmaceuticals Announces Positive Topline Data from Phase 1b/2a SWARM-P.a. Clinical Trial of Inhaled AP-PA02 in Patients with Cystic Fibrosis

Mar 6, 2023, 6:00 AM EST - 3 years ago

Armata Pharmaceuticals Announces Positive Topline Data from Phase 1b/2a SWARM-P.a. Clinical Trial of Inhaled AP-PA02 in Patients with Cystic Fibrosis

Armata Pharmaceuticals Announces Closing of $30 Million Secured Convertible Credit Agreement with Innoviva Strategic Opportunities LLC

Jan 10, 2023, 4:05 PM EST - 3 years ago

Armata Pharmaceuticals Announces Closing of $30 Million Secured Convertible Credit Agreement with Innoviva Strategic Opportunities LLC

INVA

Armata Pharmaceuticals Announces Completion of its Phase 1b/2a 'SWARM-P.a.' Study of Inhaled AP-PA02 in Cystic Fibrosis Subjects with Chronic Pulmonary Pseudomonas aeruginosa Infection

Dec 22, 2022, 8:00 AM EST - 3 years ago

Armata Pharmaceuticals Announces Completion of its Phase 1b/2a 'SWARM-P.a.' Study of Inhaled AP-PA02 in Cystic Fibrosis Subjects with Chronic Pulmonary Pseudomonas aeruginosa Infection

Armata Pharmaceuticals to Participate in the H.C. Wainwright 1st Annual Investor Conference on Bacteriophage

Nov 28, 2022, 8:00 AM EST - 3 years ago

Armata Pharmaceuticals to Participate in the H.C. Wainwright 1st Annual Investor Conference on Bacteriophage

Armata Pharmaceuticals Announces Third Quarter 2022 Results and Provides Corporate Update

Nov 9, 2022, 4:15 PM EST - 3 years ago

Armata Pharmaceuticals Announces Third Quarter 2022 Results and Provides Corporate Update

Armata Pharmaceuticals Announces Second Quarter 2022 Results and Provides Corporate Update

Aug 11, 2022, 4:05 PM EDT - 3 years ago

Armata Pharmaceuticals Announces Second Quarter 2022 Results and Provides Corporate Update

Armata Pharmaceuticals Announces Clearance of IND for Prosthetic Joint Infections

Aug 1, 2022, 8:00 AM EDT - 3 years ago

Armata Pharmaceuticals Announces Clearance of IND for Prosthetic Joint Infections

Armata Pharmaceuticals Announces First Patient Dosed in Phase 1b/2a 'diSArm' Study of AP-SA02 in Adults with Bacteremia due to Staphylococcus aureus

May 23, 2022, 8:00 AM EDT - 4 years ago

Armata Pharmaceuticals Announces First Patient Dosed in Phase 1b/2a 'diSArm' Study of AP-SA02 in Adults with Bacteremia due to Staphylococcus aureus

Armata Pharmaceuticals Announces First Quarter 2022 Results and Provides Corporate Update

May 12, 2022, 4:17 PM EDT - 4 years ago

Armata Pharmaceuticals Announces First Quarter 2022 Results and Provides Corporate Update

Armata Pharmaceuticals Announces Closing of Second and Final Tranche of $45 Million Private Placement with Innoviva

Mar 31, 2022, 4:05 PM EDT - 4 years ago

Armata Pharmaceuticals Announces Closing of Second and Final Tranche of $45 Million Private Placement with Innoviva

INVA

Trapped
Trapped Feb. 3 at 11:03 AM
$ARMP hmmm past 7 already. looks like heading to 15 again before phase 3 concludes. could there be a buyer in the wings ??? p
0 · Reply
Trapped
Trapped Feb. 2 at 10:37 PM
$ARMP a lot more coming. phase 3 going on with FDA do execute in LA office. going to be a good drug once it’s approved. just gotta wait. mean time value will continue to head north. buy and hold.
0 · Reply
History101
History101 Feb. 2 at 9:02 PM
$ARMP damn, closed today with a 15% gain, glad i added earlier today. Anyone know why the big gain today?
0 · Reply
Trapped
Trapped Feb. 2 at 6:39 PM
$ARMP i think we see $50 by end of this year.
0 · Reply
History101
History101 Feb. 2 at 5:55 PM
$ARMP $7!!
0 · Reply
Trapped
Trapped Jan. 28 at 11:30 AM
$ARMP 7 …here we come
0 · Reply
ConnorCapital
ConnorCapital Jan. 19 at 3:44 PM
$ARMP Low attention, but a break above could lead to a breakout
0 · Reply
BillionerOfKing
BillionerOfKing Jan. 16 at 8:36 PM
$ARMP Current Stock Price: $6.41 No option chain rows found for expiry 2026-01-16.
0 · Reply
King_of_the_bagholders
King_of_the_bagholders Jan. 16 at 2:41 PM
$OCG FUCK I’m good! Now if we can just get $ARMP pumping again…
0 · Reply
King_of_the_bagholders
King_of_the_bagholders Jan. 15 at 6:23 PM
$ARMP $NVO $OPEN $VZ the 7.50 options are still at a steep discount RN Not financial advice
0 · Reply
King_of_the_bagholders
King_of_the_bagholders Jan. 15 at 6:20 PM
$ARMP $NVO $OPEN $VZ Jesus I gotta start charging
0 · Reply
King_of_the_bagholders
King_of_the_bagholders Jan. 15 at 4:59 PM
Call after call after win after win after win. Calling another. $ARMP bout to print Little more of a long shot than my $VZ short, $OPEN calls last Friday or the $NVO calls. I like it a lot though
0 · Reply
marstr_
marstr_ Jan. 15 at 2:25 PM
$ARMP Structure this clean doesn’t show up often: high holds, VWAP stability, PM impulse, clear trigger level. All it needs is that RTH ignition sequence at 1.20 to open the upper runway 😤
1 · Reply
Trapped
Trapped Jan. 15 at 12:36 AM
$ARMP could be manipulated lower to allowing friends and family in at lowest prices. this may last a few days. no other reason.
0 · Reply
Alex036
Alex036 Jan. 14 at 8:09 PM
$ARMP No chance, all attempts to launch will be stopped by the owners of 70% of the shares.
0 · Reply
OtisD_Crntw36
OtisD_Crntw36 Jan. 14 at 7:50 PM
$ARMP Micro biotech, under the radar coil could turn into volume ignition with squeeze risk
0 · Reply
Alex036
Alex036 Jan. 14 at 7:46 PM
$ARMP They just shut down every attempt to move up.
0 · Reply
Alex036
Alex036 Jan. 14 at 3:19 PM
$ARMP Puppeteers in action :)
0 · Reply
King_of_the_bagholders
King_of_the_bagholders Jan. 14 at 12:13 PM
$ARMP
0 · Reply
Silmarjhg
Silmarjhg Jan. 13 at 6:32 PM
$ARMP microcap energy, float can snap, watch for volume ignition and a clean breakout hold
0 · Reply
Trapped
Trapped Jan. 13 at 4:09 PM
$ARMP good news , best news. stock goes down…wtf
0 · Reply
Almas2025
Almas2025 Jan. 13 at 3:07 PM
$ARMP worst company never buy!
0 · Reply